https://via.ritzau.dk/rss/releases/latest?lang=da&publisherId=12353927Sidst udsendte pressemeddelelserhttps://via.ritzau.dk/pressemeddelelse/14916681/leo-pharma-lancerer-loqtorzir-toripalimab-pa-hjemmemarkedet-i-danmark?lang=daLOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.Thu, 07 May 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14916681/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14911445/leo-pharma-delivers-9percent-revenue-growth-at-cer-in-q1-2026-and-strengthens-innovation-pipeline?lang=daTue, 05 May 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14911445/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14906695/leo-pharma-bolsters-rare-skin-disease-focus-through-acquisition-of-replay-gene-therapy-platform?lang=daAcquisition adds high-payload herpes simplex virus (HSV) gene therapy targeting genetic skin diseases to LEO Pharma’s pipeline and further expands the company’s presence in rare dermatology Combines LEO Pharma’s six decades of dermatology expertise with Replay’s next-generation gene therapy platform to advance innovation for patients with rare skin diseases The lead program targets dystrophic epidermolysis bullosa (DEB), a devastating genetic skin disease with significant unmet medical need.Thu, 30 Apr 2026 13:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14906695/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14882356/leo-pharma-expands-its-psoriasis-portfolio-in-china-with-nmpa-approval-of-enstilarr?lang=daNMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option for the estimated 6.5 million adults living with plaque psoriasis in the world’s largest market measured by patient numbers.1 China represents a strategically important pillar in LEO Pharma’s long-term growth, and the approval strengthens the company’s position in medical dermatology by expanding its psoriasis portfolio in an exciting market for innovative treatments. Enstilar builds on LEO Pharma’s established leadership in topical psoriasis treatments, offering a clinically proven, foam-based formulation that has been widely adopted in more than 50 markets worldwide and is supported by robust phase 3 clinical data.2,3Fri, 17 Apr 2026 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14882356/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14879115/leo-pharma-announces-fda-acceptance-of-supplemental-nda-for-anzupgor-delgocitinib-cream-for-the-treatment-of-chronic-hand-eczema-in-children-aged-12-17?lang=daThe application is supported by positive data from the pivotal Phase 3 DELTA TEEN trial in the primary and key secondary endpoints.1 If approved, ANZUPGO will be the first treatment option specifically indicated for pediatric patients aged 12–17 living with moderate to severe chronic hand eczema (CHE).Wed, 15 Apr 2026 12:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14879115/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14846251/leo-pharma-to-present-17-scientific-abstracts-at-aad-2026-highlighting-realworld-evidence-longterm-outcomes-and-patient-experience-across-multiple-dermatological-conditions?lang=daFri, 20 Mar 2026 13:30:00 GMThttps://via.ritzau.dk/pressemeddelelse/14846251/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14802108/leo-pharma-to-nominate-kasper-fangel-as-new-board-member-and-audit-committee-chair?lang=daMon, 23 Feb 2026 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14802108/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14796167/leo-pharma-delivers-10percent-revenue-growth-in-2025-and-more-than-doubles-adjusted-ebitda-margin?lang=daWed, 18 Feb 2026 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14796167/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14760503/leo-pharma-advances-anzupgor-delgocitinib-cream-to-phase-3-trial-in-lichen-sclerosus-ls?lang=daThe phase 3 trial DELTA CARE 1 will recruit up to 652 adult patients with lichen sclerosus (LS) to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle.1 The study initiation in LS is part of LEO Pharma's ambition to explore Anzupgo (delgocitinib) creme in additional indications beyond Chronic Hand Eczema (CHE), investigating the potential of delgocitinib as treatment option in skin diseases with high unmet medical need. There are currently no approved treatments specifically indicated for LS in the U.S. or in Europe. Delgocitinib cream has been shown to inhibit the activity of all four JAKs,2,3 making it a potential treatment option for people living with LS disease.Wed, 21 Jan 2026 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14760503/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14742549/leo-pharma-to-present-at-the-44th-annual-jp-morgan-healthcare-conference?lang=daWed, 07 Jan 2026 12:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14742549/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14722113/leo-pharma-appoints-marika-murto-to-lead-global-product-strategy?lang=daMarika Murto brings over 20 years of pharmaceutical expertise in product strategy, innovation, and business transformation Her appointment as SVP of Global Product Strategy will help unlock LEO Pharma’s portfolio potential, driving patient impact and supporting sustainable growthTue, 16 Dec 2025 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14722113/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14719531/leo-pharma-submits-adolescent-label-expansion-application-for-anzupgor-to-ema?lang=daLEO Pharma has submitted a label expansion application to EMA to expand Anzupgo® (delgocitinib) cream to adolescent patients (12–17 years) with moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate – the application has been accepted for review. The application is supported by results from DELTA TEEN, a phase 3 trial investigating efficacy and safety of Anzupgo® in adolescents with moderate to severe chronic hand eczema (CHE).1 The label expansion submission for adolescent patients demonstrates LEO Pharma's commitment to investigating use within relevant sub-populations where treatments can help make a fundamental difference for patients with skin diseases.Mon, 15 Dec 2025 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14719531/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14679407/leo-pharma-announces-positive-topline-32-week-key-results-in-adhand-trial?lang=daThe ADHAND trial evaluates the efficacy and safety of tralokinumab in adult patients living with atopic dermatitis with moderate-to-severe hand involvement,1 a high burden, high unmet need population.2 At Week 16, tralokinumab showed statistically significant improvement compared to placebo in all primary and key secondary endpoints such as clear or almost clear skin, itch and pain.3 The 32-week results of the ADHAND trial builds on the positive findings observed at Week 16.Mon, 17 Nov 2025 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14679407/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14661687/leo-pharma-delivers-8percent-revenue-growth-at-cer-in-9m-2025-and-updates-full-year-outlook?lang=daThu, 06 Nov 2025 08:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14661687/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14659421/leo-pharma-announces-nice-recommendation-of-reimbursement-in-england-and-wales?lang=daThe National Institute for Health and Care Excellence (NICE) has recommended the first-and-only topical treatment for adults in the United Kingdom specifically approved for moderate to severe chronic hand eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 The Technology Appraisal Guidance (TAG) means NHS organisations in England and Wales must now make Anzupgo® ▼(delgocitinib) cream available for healthcare professionals to prescribe. CHE affects around 4.4 million2,3 adults in the UK, with 70% of those with severe forms reporting problems performing everyday activities4, and 58% saying it interferes with their ability to work5.Wed, 05 Nov 2025 11:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14659421/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14654107/leo-pharma-strengthens-leadership-in-medical-dermatology-with-the-appointment-of-sophie-lamle-as-chief-development-officer?lang=daSophie Lamle brings over 20 years of experience in the pharmaceutical industry, leading innovation, clinical development, and strategic transformation. Her appointment will further strengthen LEO Pharma’s Search & Develop innovation model, unlocking value with a focus on differentiated assets.Mon, 03 Nov 2025 11:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14654107/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14620637/leo-pharma-continues-global-rollout-of-anzupgor-delgocitinib-cream-with-submission-of-new-drug-application-in-china?lang=daLEO Pharma is seeking to expand the availability of Anzupgo® (delgocitinib) cream to China, as the company announces the submission of a New Drug Application (NDA) to the National Medical Products Administration (NMPA), which has been accepted for review for adult patients with moderate to severe chronic hand eczema. The NDA is supported by results from DELTA China, a phase 3 trial with Anzupgo in Chinese adults with moderate to severe chronic hand eczema (CHE)1 along with the full clinical program of delgocitinib, which includes data from DELTA 1,2 and 3, DELTA Force and DELTA Teen.2-7 The Anzupgo NDA submission demonstrates LEO Pharma's commitment to providing additional treatment options for patients living with skin diseases in China.Thu, 16 Oct 2025 13:30:00 GMThttps://via.ritzau.dk/pressemeddelelse/14620637/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14604016/leo-pharma-closes-deal-for-spevigor?lang=daAdding Spevigo® is a significant step forward in LEO Pharma’s focused growth strategy, to accelerate and expand patients’ access to treatments for medical dermatological conditions, including generalized pustular psoriasis (GPP), a rare and severe skin condition Spevigo® (spesolimab) is a first-in-class IL-36R antagonist successfully developed and launched by Boehringer Ingelheim and approved globally for the treatment and prevention of GPP flares Spesolimab is also being investigated for the treatment of other IL-36-mediated skin diseasesWed, 01 Oct 2025 07:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14604016/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14587146/leo-pharma-presents-late-breaking-data-at-eadv-2025-showing-week-16-tralokinumab-response-predicts-long-term-response-in-moderate-to-severe-atopic-dermatitis?lang=daLate-breaking data from the ECZTEND trial show that patients with moderate-to-severe atopic dermatitis (AD), who responded to Adtralza® (tralokinumab) / Adbry® (tralokinumab-ldrm) at Week 16, maintained stable, optimal treatment outcomes for up to three years.1 Additional data presented at EADV from the real-world TRACE study further support the long-term use of tralokinumab, with sustained improvements in disease severity, quality of life, sleep, and work productivity observed over 12 months of treatment.2-4 Presented as part of LEO Pharma’s most ambitious scientific program to date at the 2025 EADV Congress, the tralokinumab data reinforce the company’s leadership in medical dermatology and its commitment to advancing innovation across its biologics’ portfolio.Fri, 19 Sep 2025 14:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14587146/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14585362/leo-pharma-presents-late-breaking-phase-3-delgocitinib-cream-data-in-adolescents-with-moderate-to-severe-chronic-hand-eczema-che?lang=daThe first late-breaking presentation was the phase 3 trial results for DELTA TEEN, showing delgocitinib cream had superior efficacy compared to cream vehicle and was generally well tolerated in adolescents, aged 12-17, with moderate to severe Chronic Hand Eczema (CHE) for whom topical corticosteroids are inadequate or inappropriate.1 In a second late-breaking presentation, pooled data from five phase 2b and phase 3 trials of delgocitinib cream confirmed a consistent safety profile for the treatment of moderate to severe CHE in adults.2 Fifteen other pieces of delgocitinib cream research formed part of LEO Pharma’s most ambitious scientific program to date at EADV 2025.3-17Thu, 18 Sep 2025 13:45:00 GMThttps://via.ritzau.dk/pressemeddelelse/14585362/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14582905/leo-pharma-presents-two-late-breaking-abstracts-for-temtokibart-reporting-positive-phase-2b-efficacy-safety-and-biomarker-results-in-moderate-to-severe-atopic-dermatitis-at-the-2025-eadv-annual-meeting-in-paris?lang=daResults presented at EADV 2025 demonstrated that investigational agent temtokibart met its primary endpoint of percentage change in the Eczema Area and Severity Index (EASI) compared with placebo for the three highest doses (600 mg, 450 mg, and 300 mg).1 Significantly greater improvements in EASI were reported as early as Week 1 for temtokibart 450mg and 300mg, and Week 2 for 600mg, vs placebo; these results were maintained up to Week 32 in 600mg and 300mg arms, despite no treatment after Week 14.1 Safety analyses revealed that temtokibart was well-tolerated with no dose-dependent AEs, a low incidence of conjunctivitis, and no signal for herpes.1Wed, 17 Sep 2025 14:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14582905/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14578407/leo-pharma-takes-centre-stage-with-its-largest-ever-scientific-programme-at-eadv-2025?lang=daFor the second year in a row, LEO Pharma delivers its largest and most ambitious scientific programme ever at the 2025 European Academy of Dermatology and Venereology (EADV), setting a new standard by presenting an unprecedented volume of scientific content for the company, with 5 late-breaking presentations and 24 regular abstracts.1-29 LEO Pharma’s scientific programme at EADV 2025 spans multiple dermatological indications, mirroring the company’s strong commitment to addressing both the most prevalent chronic skin diseases and hard-to-treat conditions.1-29 Highlights from EADV 2025 includes exciting phase 3 data in biologic injectables as well as foam and cream formulations, illustrating the breadth of therapeutic approaches represented in LEO Pharma’s medical dermatology portfolio.1-29Mon, 15 Sep 2025 13:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14578407/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14528014/leo-pharma-delivers-7percent-revenue-growth-at-cer-in-h1-2025-and-achieves-key-milestones-enabling-future-growth?lang=daMon, 18 Aug 2025 10:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14528014/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14504364/leo-pharma-announces-fda-approval-of-anzupgor-delgocitinib-cream-in-the-us?lang=daANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease.2,3 The approval represents an important milestone for LEO Pharma’s expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs.Wed, 23 Jul 2025 20:30:00 GMThttps://via.ritzau.dk/pressemeddelelse/14504364/?publisherId=12353927&lang=dafalsehttps://via.ritzau.dk/pressemeddelelse/14498323/boehringer-ingelheim-and-leo-pharma-enter-partnership-to-commercialize-and-further-develop-spevigor-spesolimab?lang=daPartnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology expertise and Boehringer’s global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operationsMon, 14 Jul 2025 11:00:00 GMThttps://via.ritzau.dk/pressemeddelelse/14498323/?publisherId=12353927&lang=dafalse